Patent Application: Antibody Heavy Chain Regions Reduce Fc Gamma Receptor Binding

ChangeBridge: Patent Apps - Peptides (C07K)

Published November 24th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085116A1) detailing antibody heavy chain constant regions modified to reduce binding to Fc gamma receptors. This modification, achieved through specific residue replacements or deletions in the hinge region, aims to decrease effector functions in antibodies and Fc fusion proteins.

View original document View source feed page

What changed

This document is a published patent application from the USPTO, specifically application US20260085116A1, filed on November 24, 2025. It describes novel antibody heavy chain constant regions with modified hinge regions designed to significantly reduce binding to Fc gamma receptors. The modification involves alterations within positions 233-236, such as glycine substitutions or deletions, which can lower Fcγ receptor binding to background levels.

While this is a patent application and not a regulatory rule, it signals potential future developments in therapeutic antibody design. Companies involved in developing antibody-based therapies or Fc fusion proteins, particularly those where effector functions are not the primary mechanism of action (e.g., receptor-ligand inhibition), may find this technology relevant for their research and development pipelines. No immediate compliance actions are required, but it represents an area of innovation in biopharmaceutical development.

Source document (simplified)

← USPTO Patent Applications

Heavy Chain Constant Regions with Reduced Binding to Fc Gamma Receptors

Application US20260085116A1 Kind: A1 Mar 26, 2026

Inventors

Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel

Abstract

The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcγ receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcγ receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.